logo

FBRX

Forte Biosciences·NASDAQ
--
--(--)
--
--(--)
0.54 / 10
Underperform

Forte Biosciences' fundamental score is 0.5/10, indicating subpar quality. Key concerns include negative net profit margin (-2972.64%) and low net profit to revenue ratio (-2164.14%), while Asset-MV shows a moderate positive factor (-0.5007). The company's revenue is growing YoY by 78.47%, but profitability remains a significant challenge. Current assets turnover is healthy at 1.78, but overall, the fundamental picture is fragile and cash flow is negative, limiting short-term upside.

Fundamental(0.54)SentimentTechnical

Analysis Checks(2/10)

Revenue-MV
Value-0.26
Score0/3
Weight11.58%
1M Return-2.92%
Net profit attributable to parent company shareholders / Net profit (%)
Value100.00
Score2/3
Weight5.35%
1M Return-1.63%
Total operating revenue (YoY growth rate %)
Value78.47
Score0/3
Weight17.38%
1M Return-6.59%
Net cash flow from operating activities / Operating revenue (%)
Value-1513.77
Score0/3
Weight20.06%
1M Return-7.70%
Net income-Revenue
Value-0.17
Score1/3
Weight2.39%
1M Return-0.69%
Net profit margin (%)
Value-2972.64
Score0/3
Weight20.90%
1M Return-8.03%
Current assets turnover ratio
Value1.78
Score1/3
Weight5.82%
1M Return-1.72%
EBIT / Total operating revenue (%)
Value-3056.43
Score0/3
Weight19.77%
1M Return-7.44%
Asset-MV
Value-0.50
Score3/3
Weight-23.76%
1M Return5.62%
Net profit / Total operating revenue (%)
Value-2164.14
Score0/3
Weight20.50%
1M Return-7.85%
Is FBRX fundamentally strong?
  • FBRX scores 0.54/10 on fundamentals and holds a Premium valuation at present. Backed by its -65.29% ROE, 0.00% net margin, -8.14 P/E ratio, 4.11 P/B ratio, and 99.51% earnings growth, these metrics solidify its Underperform investment rating.